Urology Search
Urology Urology
herpes%20simplex%20virus%20infection
HERPES SIMPLEX VIRUS INFECTION
Primary herpes simplex virus (HSV) infection is first infection with either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2.
First episode-non primary infection is infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively.
Recurrent HSV infection results from reactivation of latent virus. It is usually brought about by triggering factors eg UV light, immunosuppression.
Orolabial HSV disease is mostly caused by HSV-1 that occurs most commonly in children <5 years of age. It is transmitted through close contact with individuals who have active viral shedding.
Genital HSV disease is caused by HSV-2 that is the usual cause of herpes genitalis. It typically occurs in adults and transmitted through sexual contact.

Herpes%20simplex%20virus%20infection Treatment

Principles of Therapy

Primary Herpes Simplex Virus (HSV) Infection

  • If given within 72 hours of symptom onset, antivirals can be effective in reducing severity & duration of symptoms; however, early treatment of primary infection does not prevent recurrences
  • Choice of agent depends on cost, dosing schedule & patient preference

Recurrent Genital Herpes Simplex Virus (HSV) Infection

  • Episodic treatment for recurrent genital HSV disease may be given as a single-day patient-initiated treatment or for 5 days
  • Long-term suppressive treatment (prophylaxis) for frequent recurrences of genital HSV disease requires at least 3 months to 1 year of therapy to achieve any efficacy

Pharmacotherapy

Symptomatic Therapy

Analgesics (Oral)

  • Eg Paracetamol, Ibuprofen
  • Symptomatic relief of pain

Anesthetics (Topical)

  • Eg Benzocaine, viscous Lidocaine, Dyclonine
  • Symptomatic relief of pain
  • In theory, may cause sensitization but rarely happens in practice
  • Various topical anesthetics are available. Please see prescribing information for specific formulations in the latest MIMS

Oral Preparations

  • Symptomatic relief of ulceration & inflammation in orolabial herpes simplex virys (HSV) disease

Zinc Preparations

  • Eg Zinc oxide/glycine cream, Zinc sulfate gel
  • Shorten time of resolution of symptoms


Antiviral Therapy - Oral

Aciclovir

  • Acyclic purine nucleoside analogue that is a competitive inhibitor of viral DNA polymerase
  • Limits viral replication & stops further spread of the virus to other cells
  • Oral & Intravenous (IV) are both effective in treating HSV-1 & HSV-2
  • IV is usually reserved for severe disease or complications where hospitalization is necessary
  • Topical agent has limited efficacy for genital HSV, hence not recommended
  • Bioavailability is poor requiring frequent dosing

Famciclovir

  • Famciclovir is a prodrug of Penciclovir
  • Has higher bioavailability than Penciclovir & is rapidly converted to Penciclovir in gastrointestinal tract (GIT), blood & liver
  • Penciclovir has similar mechanism of action as Acyclovir

Valaciclovir

  • L-valine ester prodrug of Aciclovir, rapidly metabolized to Aciclovir by liver & intestine
  • Has better absorption after oral administration than Aciclovir making lower doses or lesser dosing frequency possible
  • Has been shown to decrease risk of transmission

Foscarnet

  • Pyrophosphate analogue that is a noncompetitive inhibitor of viral RNA & DNA polymerase
    • Foscarnet is virostatic & activation by thymidine kinase is not required
  • May be used for Aciclovir-resistant mucocutaneous HSV infections in immunocompromised patients

Methisoprinol or Inosiplex

  • Antiviral activity by modifying or stimulating cell-mediated immune process

Antiviral Therapy - Topical

Aciclovir - Same as above

  • Topical agent has shown limited efficacy

Cidofovir

  • May be used for Aciclovir-resistant genital infections

Docosanol

  • Inhibits fusion between the cell plasma membrane & HSV which prevents viral entry into cells & viral replication
  • Decreases healing time of recurrent herpes labialis

Penciclovir

  • Same mechanism of action as Aciclovir
  • Decreases healing time of recurrent herpes labialis

Tromantadine

  • Derivative of Amantadine w/ antiviral activity
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Standing good for heart health
Jairia Dela Cruz, 3 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Does thyroid hormone therapy provide survival benefits in subclinical hypothyroidism?
3 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.